plasma-derived FVIII/VWF concentrate
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Von Willebrand Disease
Conditions
Von Willebrand Disease
Trial Timeline
Dec 1, 2013 → Dec 1, 2026
NCT ID
NCT02472665About plasma-derived FVIII/VWF concentrate
plasma-derived FVIII/VWF concentrate is a approved stage product being developed by Grifols for Von Willebrand Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02472665. Target conditions include Von Willebrand Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02472665 | Approved | Recruiting |
Competing Products
14 competing products in Von Willebrand Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate | Roche | Pre-clinical | 23 |
| Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing Agents | Roche | Phase 3 | 77 |
| Neumega (Oprelvekin, Interleukin 11, IL-11) | Pfizer | Phase 2 | 51 |
| Oprelvekin, Interleukin 11, IL-11 | Pfizer | Phase 2 | 51 |
| recombinant interleukin-11 + recombinant interleukin-11 + recombinant interleukin-11 | Pfizer | Phase 2 | 51 |
| efanesoctocog alfa (BIVV001) | Sanofi | Phase 1 | 32 |
| Biostate | CSL | Phase 3 | 76 |
| Voncento® | CSL | Pre-clinical | 22 |
| Blood coagulation Factor VIII and vWF, human | CSL | Approved | 84 |
| Biostate® + Biostate® | CSL | Phase 2/3 | 64 |
| VWF/FVIII products | CSL | Pre-clinical | 22 |
| Biostate | CSL | Phase 3 | 76 |
| Voncento | CSL | Approved | 84 |
| Alphanate SD/HT | Grifols | Approved | 82 |